Translational Operations Specialist
Parabilis Medicines
Translational Operations Specialist
Parabilis Medicines
Develops first-in-class cancer therapeutics
About Parabilis Medicines
Parabilis Medicines is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable. The company has pioneered a new class of alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines. The company’s lead investigational medicine, zolucatetide, is the first and only direct inhibitor of the β-catenin:TCF interaction, a central node in the Wnt/β-catenin pathway that has eluded drug developers for decades. Zolucatetide is being evaluated in the clinic across multiple Wnt/β-catenin-driven diseases, including desmoid tumors, familial adenomatous polyposis (FAP) and a range of other solid tumor indications. Beyond zolucatetide, Parabilis is advancing additional Helicon-based programs focused on other challenging targets where we believe our medicines could have life-altering impact. For more information, visit www.parabilismed.com or follow us on LinkedIn.
What’s the opportunity?
Based in China, this role offers the opportunity to lead biospecimen operations for China-APAC-based clinical studies, overseeing biomarker, clinical pharmacology, and safety samples from collection through testing and data delivery. You will serve as the primary operational contact for central and specialty laboratories, maintain and reconcile sample inventories across laboratory and EDC systems, resolve discrepancies, and ensure consistent sample-handling and chain-of-custody practices. In close partnership with study sites, CROs, laboratories, and the U.S.-based Translational Operations team, you will support study documentation and training, coordinate sample transfers and regulatory filings such as HGRAC, monitor vendor performance and testing timelines, and provide clear reporting on sample status, discrepancies, and emerging operational risks.
This role requires the individual to be based in China; relocation to China will not be offered.
Biospecimen operations
Day-to-day vendor management
Reporting to the US team
What you’ll need to be successful:
Core Values
Parabilis Medicines is a team of passionate pioneers who are trailblazing the future of precision medicine with the aim of making a meaningful difference in the lives of patients. The company is committed to promoting an inspiring and flourishing working environment for all employees across the business, in all departments, and driving innovation for patient benefit.
The base salary range for this position is $75,000-$100,000, depending on experience, qualifications, and internal practices. Parabilis’s total compensation package also includes an annual target bonus, equity, and a comprehensive suite of competitivebenefits designed to support our employees’ overall well-being.
As an equal opportunity employer, Parabilis Medicines values an inclusive workplace and welcomes applicants of all backgrounds and experiences. All qualified applicants will receive consideration for employment without discrimination on the basis of race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, disability, or any other factors prohibited by law.
30 Acorn Park Drive | Cambridge, MA 02140 | www.parabilismed.com
Develops first-in-class cancer therapeutics
Parabilis Medicines advances drug discovery for cancer by developing a novel class of therapeutics called Helicon therapeutics. Its lead candidate, FOG-001, is a first-in-class inhibitor that blocks TCF-mediated β-catenin signaling, aimed at targeting common yet hard-to-treat drivers of cancer. The company uses integrated technologies to speed up discovery and scale development from research through potential commercialization. Compared with peers, Parabilis emphasizes a unique mechanism (TCF/β-catenin pathway inhibition) and a platform-driven approach designed to accelerate progression toward precision cancer therapies. The goal is to shape the future of precision medicine by delivering new treatments for previously untreatable diseases and advancing into clinical development with impactful candidates.
Explore more opportunities at Parabilis Medicines